Mounjaro and Injection site coldness - a phase IV clinical study of FDA data

Summary:

Injection site coldness is reported as a side effect among people who take Mounjaro (tirzepatide), especially for people who are female, 40-49 old, have been taking the drug for < 1 month also take Metformin, and have Type 2 diabetes.

The phase IV clinical study analyzes which people have Injection site coldness when taking Mounjaro. It is created by eHealthMe based on reports of 37,587 people who have side effects when taking Mounjaro from the FDA, and is updated regularly.

What is Mounjaro?

Mounjaro has active ingredients of tirzepatide. It is often used in weight loss. eHealthMe is studying from 37,668 Mounjaro users. Check the latest studies of Mounjaro.

What is Injection site coldness?

Injection site coldness is found to be associated with 42 drugs and 80 conditions by eHealthMe. Check the latest studies of Injection site coldness.

On Jul, 14, 2026

37,587 people reported to have side effects when taking Mounjaro.
Among them, 86 people (0.23%) have Injection site coldness.

Could Mounjaro cause Injection site coldness?

Among these 86 people:

How long have people been on Mounjaro when they have Injection site coldness? *

What is the gender of people who have Injection site coldness when taking Mounjaro? *

female: 78.82 %
male: 21.18 %

What is the age of people who have Injection site coldness when taking Mounjaro? *

What are other drugs people take besides Mounjaro? *

Metformin: 7 people, 8.14%
Trulicity: 2 people, 2.33%

What are other side effects people have besides Injection site coldness? *

Injection Site Pain: 41 people, 47.67%
Injection Site Haemorrhage (bleeding from injection site): 8 people, 9.30%
Appetite - Increased (increased appetite is when you want to eat much more often or in larger quantities than your body requires): 6 people, 6.98%
Nausea (feeling of having an urge to vomit): 6 people, 6.98%
Appetite - Decreased (decreased appetite occurs when you have a reduced desire to eat): 4 people, 4.65%
Injection Site Bruising: 4 people, 4.65%
Visual Impairment: 3 people, 3.49%
Injection Site Swelling: 3 people, 3.49%
Dehydration (dryness resulting from the removal of water): 2 people, 2.33%
Fatigue (feeling of tiredness): 2 people, 2.33%

What are the existing conditions these people have? *

Type 2 Diabetes: 21 people, 24.42%
Glucose Tolerance Impaired (blood glucose is raised beyond normal levels, but not high enough to warrant a diabetes diagnosis): 11 people, 12.79%
Weight Decreased: 7 people, 8.14%
Diabetes: 6 people, 6.98%
Glycosylated Haemoglobin Increased: 3 people, 3.49%
Glycosylated Haemoglobin: 2 people, 2.33%
Blood Glucose Abnormal: 1 person, 1.16%

* Approximation only. Some reports may have incomplete information.

Do you take Mounjaro and have Injection site coldness?

- Check whether Injection site coldness is associated with a drug or a condition
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously

Related studies:

Effectiveness of, long term effects of, and alternative drugs to Mounjaro:

Mounjaro (37,668 reports)

Browse all side effects of Mounjaro:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all the drugs that are associated with Injection site coldness:

Injection site coldness (42 drugs)

Browse all the conditions that are associated with Injection site coldness:

Injection site coldness (80 conditions)

How the study uses the data?

The study uses data from the FDA. It is based on tirzepatide (the active ingredients of Mounjaro) and Mounjaro (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.